Use and method of HGH application
Group 1 was treated orally with 15 drops, 3 times a day for 5 months with the homeopathic solution of 21st Century HGH potentized to 30X, which was bottled in 30m1 amber bottles. Group 2 was treated with 21st Century HGH in the same manner as Group 1 but, in addition, were treated with the homeopathic formulation of HE potentized to 3X in quantities of 15 drops, 3 times a day orally, during 5 months. Group 3, which served as the control, was treated with a placebo, administered orally in quantities of 15 drops 3 times a day during 5 months.
All showed a statistically significant increase in plasmatic levels of IGF-I, although the percentage increase of said hormone was greatest in Group 1 (p < 0.001). Blood glucose showed a statistically significant increase in those treated with only 21st Century HGH (p < 0.05). IgG decreased in Group 1 (p < 0.01) and in Group 2 (p < 0.02). Patients' weight and excess body fat (measured as the corporal fat level in excess of predicted normal prophylactic ranges for each participant given their sex, age and height) decreased more in groups 1 and 2 (p < 0.001 and p < 0.01).
Currently, modifications that occur with aging in the human growth hormone axis (hypothalamus-hypophysis-liver) are well known. The decrease in the production of HGH by the anterior hypophysis, stands out, as well as the production of Somatomedin-C (IGF-I), by human growth hormone stimulus in the liver.
On the other hand, studies which have used human recombinant growth hormone or GHRH in the elderly have shown that this produces an increase in plasmatic levels of Somatomedin-C and glycemia during fasting. The results that we obtained with the use of the homeopathic formulation indicated that the 2 groups that used said preparation, showed an average percentage increase up to 130 (P < 0.001) in plasma levels of IGF-I, and in some cases up to 160 if we take into consideration the average plus a standard error to the right.
These increases of IGF-I are the firmest bases we have to affirm that the homeopathic formulation exercises its action at least at the liver level; we do not believe that said formulation will act at the hypothalmic level by increasing the quantities of GHRH or by inhibiting the somatostatin (SRIF).
Rudman and his group studied the effects of the administration of HGH for six months in healthy men over the age of 60 whose low levels of IGF-I were similar to those observed in young men. The preceding resulted in a significant increase in lean body mass (14.4 percent) and a slight decrease in adipose tissue mass (8.8 percent). There was a tendency for the skin to thicken and a minimum increase in bone mass (1.6 percent) was found. They note that in other studies no benefits were found by adding it in patients with osteoporosis who were being treated with calcitonin.
Other studies have also shown that old age is associated with a decrease in the levels of IGF-I nevertheless, when human growth hormone is administered to the elderly, IGF-1 increases and the same as when GHRH is administered. These findings suggest that the decrease of IGF-I observed in the elderly reflects a decrease in human growth hormone beyond that of insular resistance to the effect of HGH.
Aging in humans is also associated with a reduction in muscular and bone mass and with an increase in body fat,'' which suggests that the deficiency of human growth hormone in the elderly can be partially responsible for these changes in body composition. On the other hand, the field of homeopathy has also been influenced by the advances in research in the use of human growth hormone in the elderly.
Continued Part 3: HGH Effects